Patient clinical characteristics of B-cell lymphoma (NCT03101709)
| ID | Age/gender | Lines of prior therapy | Previous treatment | Marrow blasts before therapy | Lymphocyte depletion | WBC (109/L) | LYM (109/L) | Peripheral blood collection (mL) | PBMC collection (×107) | CD3+ T cell collection (×107) | CD3+ T cells for culture (×107) | Transfection efficiency (%) | CAR dose (×106/kg) | CRS grade | Response (2 months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 52/M | 6 | C | Y | FC | 8.43 | 3.61 | 100 | 6.26 | 3.16 | 2.4 | 37 | 3.0 | 1 | CR |
| 2 | 39/F | 3 | C | N | FC | 2.54 | 0.76 | 100 | 5.30 | 2.70 | 2.4 | 31 | 2.0 | 0 | PR |
| 3 | 35M | 3 | C | Y | FC | 6.15 | 1.74 | 100 | 6.88 | 4.69 | 2.4 | 42 | 1.5 | 2 | CR |
| 4 | 60/F | 3 | C | N | FC | 3.25 | 0.85 | 100 | 4.90 | 2.60 | 2.4 | 45 | 1.5 | 0 | PD |
| 5 | 51/F | 3 | C, R, T | N | FC | 5.45 | 0.49 | 100 | 3.95 | 2.13 | 2.0 | 30 | 1.5 | 0 | CR |
| 6 | 62/M | 4 | C | N | FC | 2.66 | 0.83 | 100 | 4.96 | 2.66 | 2.4 | 20 | 1.0 | 0 | PD |
| 7 | 58/F | 4 | C | N | FC | 2.52 | 0.75 | 100 | 7.33 | 4.90 | 2.4 | 60 | 2.0 | 2 | PR |
| 8 | 49/M | 3 | C | N | FC | 11.60 | 0.91 | 100 | 8.00 | 3.46 | 2.4 | 45 | 1.5 | 1 | CR |
| 9 | 38/M | 3 | C | N | FC | 4.35 | 1.47 | 100 | 7.40 | 5.30 | 2.4 | 39 | 1.5 | 1 | PR |
All patients were followed up until February 5, 2018; M, male; F, female; C, chemotherapy; R, radiation therapy; T, hemopoietic stem-cell transplant; CRS, cytokine release syndrome; PBMC, peripheral blood mononuclear cell; WBC, white blood cell, normal range (3.5–9.5) × 109/L; LYM, lymphocyte count, normal range (1.1–3.2) × 109/L; FC, fludarabine, cyclophosphamide; N, no; Y, yes; CR, complete remission; PR, partial remission; PD, progressive disease.